Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 12, 2018

View Archived Issues

Cellenkos manufacturing facility is successfully registered as GMP compliant with the FDA

Acesion Pharma cleared to conduct phase I study of AP-30663

Janssen submits MAA to EMA for apalutamide for nonmetastatic CRPC

Phase II trials of BI-409306 in Alzheimer's disease do not meet efficacy endpoints

Novo Nordisk's Ozempic approved in E.U.

Boehringer Ingelheim initiates phase I study of BI-1291583

Aravive studies AVB-S6-500 in healthy volunteers

Lundbeck updates progress of fourth quarter 2017

Tychan initiates phase Ia trial of first-in-class Zika antibody tyzivumab

Puma presents clinical data on neratinib in patients with HER2/3 mutant cancers

Phase III quality of life data reported for turoctocog alfa pegol in hemophilia A

Kissei presents novel CGRP antagonists

Retrophin divulges new pantetheine derivatives for neurodegeneration

New phase I/II trial evaluates lentiviral gene transfer for SCID-X1

Achaogen discloses novel ACC inhibitors for bacterial infections

Novel USP19 inhibitors presented by Almac Discovery

Toray Industries identifies MALT1 inhibitors

Roivant and Poxel sign development and license agreement for imeglimin

Seattle Genetics and Pieris Pharmaceuticals enter immune-oncology collaboration

Scholar Rock's SRK-015 antibody inhibits muscle wasting by binding myostatin precursors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...